Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD 1st-line treatment in early-stage unfavorable #Hodgkin lymphoma at @ASH_hematology: https://bit.ly/2LgW0g5  🩺🧵👇 #lymsm #immunotherapy #ASH20
In NIVAHL 109 patients received either concomitant 4x N-AVD or sequential 2x nivo, 2x N-AVD, 2x AVD each followed by 30Gy IS-RT. As previously reported, disease control was excellent with 1y FU and very early near-complete resolution of MTV with histologic remission was observed.
With 2y median FU no further PFS/OS events occured and all patients with residual PET-positivity after completion of treatment (i.e. PR by central review) converted to CR without further treatment. 2-year PFS: 100% and 98%, respectively, 2-year OS: 100%.
With 2y median FU no further PFS/OS events occured and all patients with residual PET-positivity after completion of treatment (i.e. PR by central review) converted to CR without further treatment. 2-year PFS: 100% and 98%, respectively, 2-year OS: 100%.
With 2y median FU no further PFS/OS events occured and all patients with residual PET-positivity after completion of treatment (i.e. PR by central review) converted to CR without further treatment. 2-year PFS: 100% and 98%, respectively, 2-year OS: 100%.
Toxicities during FU were mostly considered related to chemo- and/or radiotherapy except hypothyroidism. While 18% of pts. required any medication for late AEs, at last FU no patient required corticosteroids. Sequential lung function assessments didn't reveal relevant changes.
Toxicities during FU were mostly considered related to chemo- and/or radiotherapy except hypothyroidism. While 18% of pts. required any medication for late AEs, at last FU no patient required corticosteroids. Sequential lung function assessments didn't reveal relevant changes.
Toxicities during FU were mostly considered related to chemo- and/or radiotherapy except hypothyroidism. While 18% of pts. required any medication for late AEs, at last FU no patient required corticosteroids. Sequential lung function assessments didn't reveal relevant changes.
Anti-PD1 1st-line treatment in early-stage unfavorable HL is feasible and highly effective. Remarkable MTV reduction ( @CCR_AACR) & histologic CR on re-biopsies days after 1st nivo ( @BloodJournal) pose the question, whether all pts. require the full NIVAHL treatment?
Our upcoming phase II INDIE trial will address this question and evaluate an individualized tislelizumab-based PET-guided 1st-line treatment incl. pts. >60y. In INDIE, optimally responding pts. will only receive the anti-PD1 antibody and I really look forward to the trial & data
You can follow @BroeckelmannPJ.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.